カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界のレジオネラ検査市場（～2027年）：検査種類別（培養、尿中抗原検査、DFA、PCR）、用途別（水＆IVD検査（尿、血液））、エンドユーザー別（病院、クリニック、診断研究所、水処理産業）、地域別

【英語タイトル】Legionella Testing Market by Test Type (Culture, Urinary Antigen Test, DFA, PCR), Application (Water & IVD Testing (Urine, Blood)), End User (Hospitals, Clinics, Diagnostic Labs, Water Treatment Industries), Region - Global Forecast to 2027

MarketsandMarketsが出版した調査資料（MD8150-22）・商品コード：MD8150-22
・発行会社（調査会社）：MarketsandMarkets
・発行日：2022年8月17日
・ページ数：203
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後24時間以内）
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥722,700見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥970,900見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,189,900見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
MarketsandMarkets社の最新調査レポートによると、世界のレジオネラ検査市場規模は、2022年296百万ドルから2027年439百万ドルまで年平均8.2％拡大すると見込まれています。当書では、レジオネラ検査の世界市場について多面的に調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、検査種類別（培養検査、尿中抗原検査、DFA検査、PCR検査）分析、用途別（水中レジオネラ検査、IVDレジオネラ検査）分析、最終用途別（水＆その他産業、診断研究所、病院、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報などの項目をまとめました。なお、当書に掲載されている企業情報には、Thermo Fisher Scientific, Inc. (US)、Merck KGaA (Germany)、Bio-Rad Laboratories, Inc. (US)、IDEXX Laboratories, Inc. (US)、bioMérieux S.A. (France)、Becton, Dickinson, and Company (US)、Alere, Inc. (US)、Eurofins Scientific (Luxembourg)、Roche Diagnostics (Switzerland)、Pall Corporation (Danaher) (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のレジオネラ検査市場規模：検査種類別
- 培養検査の市場規模
- 尿中抗原検査の市場規模
- DFA検査の市場規模
- PCR検査の市場規模
・世界のレジオネラ検査市場規模：用途別
- 水中レジオネラ検査の市場規模
- IVDレジオネラ検査の市場規模
・世界のレジオネラ検査市場規模：最終用途別
- 水＆その他産業における市場規模
- 診断研究所における市場規模
- 病院における市場規模
- その他用途における市場規模
・世界のレジオネラ検査市場規模：地域別
- 北米のレジオネラ検査市場規模
- ヨーロッパのレジオネラ検査市場規模
- アジア太平洋のレジオネラ検査市場規模
- 中南米のレジオネラ検査市場規模
- 中東・アフリカのレジオネラ検査市場規模
・競争状況
・企業情報
❖ レポートの概要 ❖

“世界のレジオネラ検査市場は、2022年2億9600万米ドルから2027年4億3900万米ドルまで、CAGR8.2%で成長すると予測”
この市場の成長の主な原動力は、レジオネラ関連疾患の有病率の上昇と相まって高齢者人口が増加していることと、迅速診断の需要が高まっていることです。

“予測期間中、検査タイプ別ではPCRセグメントが最も高い成長率を記録”
レジオネラ検査市場は、製品別に培養法、尿中抗原検査、直接蛍光抗体検査、PCRに区分されます。2021年、レジオネラ検査市場で最も高い成長率を占めたのはPCR分野でした。市場成長の主な要因は、その迅速性、汎用性、簡便性にあります。

“水・その他産業セグメントが最も高いCAGRを占める見込み”
エンドユーザーに基づいて、レジオネラ検査市場は、病院、診断ラボ、水＆その他の産業、およびその他のエンドユーザーにセグメント化されています。2021年には、水・その他の産業セグメントが最も高い成長率を占めました。これは、人口増加と都市化、新たな水資源に対する需要の増加に起因しています。

“アジア太平洋：レジオネラ検査市場で最も急成長している地域”
世界のレジオネラ検査市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分されます。アジア太平洋地域は予測期間中に最も高いCAGRを記録すると予測されています。病気の早期診断や定期的な健康診断に関する認識を高めるための政府の取り組みなどが、その要因となっています。

本レポートのために実施した一次インタビューは以下のように分類されます：
- 企業タイプ別 ティア1：40％、ティア2：30％、ティア3：30％
- 役職別 Cレベル：27％、Dレベル：18％、その他：55％
- 地域別 北米：51％、欧州：21％、アジア太平洋地域：18％、中南米：6％、中東・アフリカ：4％

レポート掲載企業リスト
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (US)
• IDEXX Laboratories, Inc. (US)
• bioMérieux S.A. (France)
• Becton, Dickinson, and Company (US)
• Alere, Inc. (US)
• Eurofins Scientific (Luxembourg)
• Roche Diagnostics (Switzerland)
• Pall Corporation (Danaher) (US)
• Quidel Corporation (US)
• 栄研化学（日本）
• Hologic, Inc. (US)
• QIAGEN (Germany)
• タカラバイオ株式会社（日本）
• Environmental Safety Technologies, Inc. (US)
• Hydrosense (Scotland)
• Accepta Ltd. (UK)
• LuminUltra Technologies Ltd. (Canada)
• Pro-Lab Diagnostics, Inc. (Canada)
• BioAlert Solutions (Canada)
• Pacific Water Technology (Australia)
• Aquacert Ltd. (UK)
• DTK Water (UK)
• Sens Solutions (Spain)
• Genomadix, Inc. (US)
• Phigenics, LLC (US)

調査範囲
本調査レポートは、世界のレジオネラ検査市場を詳細に掲載しています。検査タイプ、用途、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの会社概要、最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、レジオネラ検査市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、および課題に関する情報を提供することを可能にします。

❖ レポートの目次 ❖

1 INTRODUCTION 27
1.1 STUDY OBJECTIVES 27
1.2 MARKET DEFINITION 27
TABLE 1 INCLUSIONS AND EXCLUSIONS 27
1.3 STUDY SCOPE 28
1.4 YEARS CONSIDERED 28
1.5 CURRENCY CONSIDERED 29
1.6 LIMITATIONS 29
1.7 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
FIGURE 1 LEGIONELLA TESTING MARKET: RESEARCH DESIGN METHODOLOGY 30
2.1.1 SECONDARY DATA 31
2.1.1.1 Key data from secondary sources 31
2.1.2 PRIMARY DATA 32
2.1.2.1 Key data from primary sources 33
TABLE 2 KEY DATA FROM PRIMARY SOURCES 33
FIGURE 2 KEY INDUSTRY INSIGHTS 34
2.1.2.2 Breakdown of primary interviews 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (LEGIONELLA TESTING MARKET) 34
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
2.2.1 BOTTOM-UP APPROACH 36
2.2.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.2.1.2 Approach 2: Presentations of companies and primary interviews 36
2.2.1.3 Growth forecast 37
2.2.1.4 CAGR projections 37
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.2.2 TOP-DOWN APPROACH 38
FIGURE 7 LEGIONELLA TESTING MARKET: TOP-DOWN APPROACH 38
2.3 DATA TRIANGULATION 39
FIGURE 8 DATA TRIANGULATION METHODOLOGY 39
2.4 RESEARCH ASSUMPTIONS 40
2.5 LIMITATIONS AND RISK ASSESSMENT 40
FIGURE 9 LIMITATIONS: LEGIONELLA TESTING MARKET 40
TABLE 3 RISK ASSESSMENT: LEGIONELLA TESTING MARKET 41
3 EXECUTIVE SUMMARY 42
FIGURE 10 LEGIONELLA TESTING MARKET, BY TEST TYPE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 11 LEGIONELLA TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 43
FIGURE 12 LEGIONELLA TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 43
FIGURE 13 LEGIONELLA TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 44
4 PREMIUM INSIGHTS 45
4.1 LEGIONELLA TESTING MARKET OVERVIEW 45
FIGURE 14 GROWING PREVALENCE OF LEGIONELLA-RELATED ILLNESS AND RISING GERIATRIC POPULATION TO DRIVE MARKET GROWTH 45
4.2 LEGIONELLA TESTING MARKET SHARE, BY TEST TYPE, 2022 VS. 2027 46
FIGURE 15 PCR SEGMENT WILL CONTINUE TO DOMINATE MARKET IN 2027 46
4.3 LEGIONELLA TESTING MARKET SHARE, BY APPLICATION, 2022 VS. 2027 46
FIGURE 16 WATER TESTING SEGMENT TO HOLD LARGEST MARKET SHARE 46
4.4 LEGIONELLA TESTING MARKET SHARE, BY END USER, 2022 VS. 2027 47
FIGURE 17 WATER & OTHER INDUSTRIES TO CONTINUE TO DOMINATE MARKET IN 2027 47
4.5 LEGIONELLA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 19 LEGIONELLA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
5.2.1 DRIVERS 49
5.2.1.1 Rising incidence of pneumonia and legionella-related illnesses 49
5.2.1.2 Increasing demand for rapid advanced diagnostic technologies 49
5.2.1.3 Technological advancements in bacterial testing 49
5.2.1.4 Stringent regulations for regular water testing 50
5.2.2 RESTRAINTS 51
5.2.2.1 Lack of reimbursement policies 51
5.2.3 OPPORTUNITIES 51
5.2.3.1 Opportunities in growing economies 51
5.2.3.2 Legal requirements for water testing 51
5.2.4 CHALLENGES 52
5.2.4.1 Difficulties in detection 52
5.2.4.2 Limited awareness in underdeveloped countries 52
5.2.4.3 High health costs associated with Legionella 53
5.3 PRICING ANALYSIS 53
TABLE 4 AVERAGE SELLING PRICE OF LEGIONELLA TESTING PRODUCTS (2022) 53
5.4 PATENT ANALYSIS 54
FIGURE 20 PATENT ANALYSIS FOR MOTORIZED LEGIONELLA TESTING DEVICES 54
TABLE 5 LIST OF KEY PATENTS 55
5.5 VALUE CHAIN ANALYSIS 57
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES 57
5.6 SUPPLY CHAIN ANALYSIS 58
FIGURE 22 LEGIONELLA TESTING MARKET: SUPPLY CHAIN ANALYSIS 58
5.7 ECOSYSTEM/MARKET MAP 59
FIGURE 23 LEGIONELLA TESTING MARKET: ECOSYSTEM/MARKET MAP 59
TABLE 6 LEGIONELLA TESTING MARKET: ROLE IN ECOSYSTEM 60
5.8 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 7 LEGIONELLA TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.8.1 THREAT OF NEW ENTRANTS 61
5.8.2 THREAT OF SUBSTITUTES 61
5.8.3 BARGAINING POWER OF BUYERS 61
5.8.4 BARGAINING POWER OF SUPPLIERS 61
5.8.5 DEGREE OF COMPETITION 61
5.9 PESTEL ANALYSIS 62
5.9.1 POLITICAL FACTORS 62
5.9.2 ECONOMIC FACTORS 62
5.9.3 SOCIAL FACTORS 62
5.9.4 TECHNOLOGICAL FACTORS 63
5.9.5 ENVIRONMENTAL FACTORS 63
5.9.6 LEGAL FACTORS 63
5.10 REGULATORY LANDSCAPE 64
TABLE 8 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 9 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
TABLE 10 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
TABLE 11 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 66
5.10.1 NORTH AMERICA 66
5.10.1.1 US 66
5.10.1.2 Canada 67
5.10.2 EUROPE 67
5.10.3 ASIA PACIFIC 67
5.10.3.1 Japan 67
5.10.3.2 India 67
5.10.4 LATIN AMERICA 68
5.10.4.1 Brazil 68
5.10.4.2 Mexico 68
5.10.5 MIDDLE EAST 68
5.10.6 AFRICA 69
5.11 TRADE ANALYSIS 69
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 69
TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 69
TABLE 14 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION) 69
5.12 TECHNOLOGY ANALYSIS 70
5.13 KEY CONFERENCES & EVENTS IN 2022–2023 71
TABLE 15 LEGIONELLA TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS 71
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
FIGURE 24 REVENUE SHIFT IN THE LEGIONELLA TESTING MARKET 72
5.15 KEY STAKEHOLDERS & BUYING CRITERIA 72
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF LEGIONELLA TESTING PRODUCTS 72
TABLE 16 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF LEGIONELLA TESTING PRODUCTS 73
5.15.2 BUYING CRITERIA 73
FIGURE 26 KEY BUYING CRITERIA FOR LEGIONELLA TESTING PRODUCTS 73
TABLE 17 KEY BUYING CRITERIA FOR LEGIONELLA TESTING PRODUCTS 73
5.16 CASE STUDIES 74
6 LEGIONELLA TESTING MARKET, BY TEST TYPE 75
6.1 INTRODUCTION 76
TABLE 18 LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 76
6.2 PCR 76
6.2.1 INCREASED USAGE OF PCR TO SUPPORT MARKET GROWTH 76
TABLE 19 KEY PCR PRODUCTS AVAILABLE IN THE MARKET 77
TABLE 20 LEGIONELLA TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION) 77
6.3 CULTURE METHODS 77
6.3.1 HIGHER SPECIFICITY AND SENSITIVITY TO DRIVE MARKET 77
TABLE 21 KEY CULTURE METHODS AVAILABLE IN THE MARKET 78
TABLE 22 LEGIONELLA TESTING MARKET FOR CULTURE METHODS, BY REGION, 2020–2027 (USD MILLION) 79
6.4 URINARY ANTIGEN TESTS 79
6.4.1 RAPID OUTCOMES TO DRIVE MARKET GROWTH 79
TABLE 23 KEY URINARY ANTIGEN TESTS AVAILABLE IN THE MARKET 79
TABLE 24 LEGIONELLA TESTING MARKET FOR URINARY ANTIGEN TESTS, BY REGION, 2020–2027 (USD MILLION) 80
6.5 DIRECT FLUORESCENT ANTIBODY TESTS 80
6.5.1 RAPIDITY AND EASE OF USE TO BOOST ADOPTION OF TESTS 80
TABLE 25 LEGIONELLA TESTING MARKET FOR DIRECT FLUORESCENT ANTIBODY TESTS, BY REGION, 2020–2027 (USD MILLION) 80
7 LEGIONELLA TESTING MARKET, BY APPLICATION 81
7.1 INTRODUCTION 82
TABLE 26 LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82
7.2 WATER TESTING 82
TABLE 27 LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 83
TABLE 28 LEGIONELLA TESTING MARKET FOR WATER TESTING, BY REGION, 2020–2027 (USD MILLION) 83
7.2.1 PCR 83
7.2.1.1 Rapid diagnosis to spur segment growth 83
TABLE 29 WATER TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION) 84
7.2.2 MICROBIAL CULTURE 84
7.2.2.1 Long incubation periods make isolation difficult, affecting adoption of culture techniques 84
TABLE 30 WATER TESTING MARKET FOR MICROBIAL CULTURE, BY REGION, 2020–2027 (USD MILLION) 85
7.2.3 DFA STAIN 85
7.2.3.1 High test specificity to drive adoption of DFA staining 85
TABLE 31 WATER TESTING MARKET FOR DFA STAIN, BY REGION, 2020–2027 (USD MILLION) 86
7.3 IVD TESTING 86
TABLE 32 LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 86
TABLE 33 LEGIONELLA TESTING MARKET FOR IVD TESTING, BY REGION, 2020–2027 (USD MILLION) 87
7.3.1 URINE ANTIGEN TESTS 87
7.3.1.1 Rapid and early diagnosis capabilities to drive market growth 87
TABLE 34 IVD TESTING MARKET FOR URINE ANTIGEN TESTS, BY REGION, 2020–2027 (USD MILLION) 88
7.3.2 PCR 88
7.3.2.1 Emergence of advanced technologies such as qRT-PCR to support market growth 88
TABLE 35 IVD TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION) 88
7.3.3 BLOOD CULTURE & SPUTUM TESTS 89
7.3.3.1 Longer incubation period resulting in lower adoption of blood culture techniques 89
TABLE 36 IVD TESTING MARKET FOR BLOOD CULTURE & SPUTUM TESTS, BY REGION, 2020–2027 (USD MILLION) 89
7.3.4 DFA STAIN 90
7.3.4.1 Sensitivity variations affect use of DFA staining in IVD tests 90
TABLE 37 IVD TESTING MARKET FOR DFA STAIN, BY REGION, 2020–2027 (USD MILLION) 90
7.4 OTHER APPLICATIONS 90
TABLE 38 LEGIONELLA TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 91
8 LEGIONELLA TESTING MARKET, BY END USER 92
8.1 INTRODUCTION 93
TABLE 39 LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 93
8.2 WATER & OTHER INDUSTRIES 93
8.2.1 STRINGENT REGULATIONS AND GROWING POPULATION TO DRIVE MARKET GROWTH 93
TABLE 40 LEGIONELLA TESTING MARKET FOR WATER & OTHER INDUSTRIES, BY REGION, 2020–2027 (USD MILLION) 94
8.3 DIAGNOSTIC LABORATORIES 94
8.3.1 HEALTHCARE INFRASTRUCTURE IMPROVEMENTS TO BOOST MARKET GROWTH 94
TABLE 41 LEGIONELLA TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 95
8.4 HOSPITALS 95
8.4.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH 95
TABLE 42 LEGIONELLA TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 96
8.5 OTHER END USERS 96
TABLE 43 LEGIONELLA TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 96
9 LEGIONELLA TESTING MARKET, BY REGION 97
9.1 INTRODUCTION 98
TABLE 44 LEGIONELLA TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 98
9.2 NORTH AMERICA 98
FIGURE 27 NORTH AMERICA: LEGIONELLA TESTING MARKET SNAPSHOT 99
TABLE 45 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 46 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 100
TABLE 47 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100
TABLE 48 NORTH AMERICA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 100
9.2.1 US 101
9.2.1.1 Strong presence of major market players to drive growth 101
TABLE 49 US: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 101
TABLE 50 US: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
TABLE 51 US: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 52 US: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 102
TABLE 53 US: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 102
9.2.2 CANADA 103
9.2.2.1 Rising incidence of lifestyle diseases to drive market growth 103
TABLE 54 CANADA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 103
TABLE 55 CANADA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103
TABLE 56 CANADA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 57 CANADA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 104
TABLE 58 CANADA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 104
9.3 EUROPE 105
TABLE 59 EUROPE: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 60 EUROPE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 106
TABLE 61 EUROPE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 106
TABLE 62 EUROPE: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 106
9.3.1 GERMANY 107
9.3.1.1 Germany dominates Legionella testing market in Europe 107
TABLE 63 GERMANY: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 107
TABLE 64 GERMANY: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107
TABLE 65 GERMANY: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 66 GERMANY: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 108
TABLE 67 GERMANY: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 108
9.3.2 UK 109
9.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth 109
TABLE 68 UK: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 109
TABLE 69 UK: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 70 UK: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 71 UK: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 110
TABLE 72 UK: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 111
9.3.3 FRANCE 111
9.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth 111
TABLE 73 FRANCE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 111
TABLE 74 FRANCE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112
TABLE 75 FRANCE: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 76 FRANCE: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 77 FRANCE: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 113
9.3.4 ITALY 113
9.3.4.1 Adoption of advanced diagnostic technologies to drive market growth 113
TABLE 78 ITALY: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 114
TABLE 79 ITALY: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 80 ITALY: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 81 ITALY: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 82 ITALY: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 115
9.3.5 SPAIN 115
9.3.5.1 Rising geriatric population to drive market growth 115
TABLE 83 SPAIN: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 116
TABLE 84 SPAIN: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116
TABLE 85 SPAIN: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 86 SPAIN: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 117
TABLE 87 SPAIN: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 117
9.3.6 REST OF EUROPE 118
TABLE 88 ROE: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 118
TABLE 89 ROE: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 90 ROE: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 91 ROE: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 92 ROE: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 120
9.4 ASIA PACIFIC 120
FIGURE 28 APAC: LEGIONELLA TESTING MARKET SNAPSHOT 121
TABLE 93 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 94 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 122
TABLE 95 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 96 ASIA PACIFIC: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 123
9.4.1 CHINA 123
9.4.1.1 Growing public access to modern healthcare to drive market growth 123
TABLE 97 CHINA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 124
TABLE 98 CHINA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 99 CHINA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 100 CHINA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 101 CHINA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 125
9.4.2 JAPAN 125
9.4.2.1 Universal healthcare reimbursement policy to drive market growth 125
TABLE 102 JAPAN: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 126
TABLE 103 JAPAN: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 104 JAPAN: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 105 JAPAN: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 106 JAPAN: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 127
9.4.3 INDIA 128
9.4.3.1 Increasing private & public investments in healthcare to drive market growth 128
TABLE 107 INDIA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 128
TABLE 108 INDIA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 109 INDIA: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 110 INDIA: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 129
TABLE 111 INDIA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 130
9.4.4 REST OF ASIA PACIFIC 130
TABLE 112 ROAPAC: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 131
TABLE 113 ROAPAC: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 114 ROAPAC: LEGIONELLA TESTING MARKET FOR WATER TESTING, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 115 ROAPAC: LEGIONELLA TESTING MARKET FOR IVD TESTING, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 116 ROAPAC: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 132
9.5 LATIN AMERICA 132
9.5.1 RISING HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS 132
TABLE 117 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 133
TABLE 118 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
TABLE 119 LATIN AMERICA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 134
9.6 MIDDLE EAST & AFRICA 134
9.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH 134
TABLE 120 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 135
TABLE 121 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
TABLE 122 MIDDLE EAST & AFRICA: LEGIONELLA TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 135
10 COMPETITIVE LANDSCAPE 136
10.1 OVERVIEW 136
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 136
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE LEGIONELLA TESTING MARKET 136
TABLE 123 STRATEGIC DEVELOPMENTS REPORTED 136
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 137
FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS 137
10.4 MARKET SHARE ANALYSIS 138
10.4.1 LEGIONELLA TESTING MARKET 138
FIGURE 30 LEGIONELLA TESTING MARKET SHARE, BY KEY PLAYER (2021) 138
TABLE 124 LEGIONELLA TESTING MARKET: DEGREE OF COMPETITION 139
10.5 COMPANY EVALUATION MATRIX 140
10.5.1 LIST OF EVALUATED VENDORS 140
10.5.2 STARS 140
10.5.3 EMERGING LEADERS 140
10.5.4 PERVASIVE PLAYERS 140
10.5.5 PARTICIPANTS 140
FIGURE 31 LEGIONELLA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 141
10.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021) 142
10.6.1 PROGRESSIVE COMPANIES 142
10.6.2 STARTING BLOCKS 142
10.6.3 RESPONSIVE COMPANIES 142
10.6.4 DYNAMIC COMPANIES 142
FIGURE 32 LEGIONELLA TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 143
10.7 COMPETITIVE BENCHMARKING 144
10.7.1 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS 144
FIGURE 33 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN LEGIONELLA TESTING MARKET 144
TABLE 125 LEGIONELLA TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 144
TABLE 126 PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 145
TABLE 127 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 145
TABLE 128 LEGIONELLA TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES 145
10.8 COMPETITIVE SCENARIO 146
10.8.1 PRODUCT LAUNCHES 146
TABLE 129 LEGIONELLA TESTING MARKET: KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 146
10.8.2 DEALS 146
TABLE 130 LEGIONELLA TESTING MARKET: KEY DEALS 146
10.8.3 OTHER DEVELOPMENTS 147
TABLE 131 LEGIONELLA TESTING MARKET: OTHER DEVELOPMENTS 147
11 COMPANY PROFILES 148
(Business Overview, Products Offered, Recent Developments, MnM View SWOT analysis) *
11.1 KEY PLAYERS 148
11.1.1 INDUSTRIAL/WATER 148
11.1.1.1 Thermo Fisher Scientific 148
TABLE 132 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 148
FIGURE 34 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2021) 149
11.1.1.2 Merck KGAA 152
TABLE 133 MERCK KGAA: BUSINESS OVERVIEW 152
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021) 153
11.1.1.3 Bio-Rad Laboratories 156
TABLE 134 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 156
FIGURE 36 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021) 157
11.1.1.4 IDEXX Laboratories 159
TABLE 135 IDEXX LABORATORIES: BUSINESS OVERVIEW 159
FIGURE 37 IDEXX LABORATORIES: COMPANY SNAPSHOT (2021) 160
11.1.1.5 Biomérieux SA 162
TABLE 136 BIOMÉRIEUX SA: BUSINESS OVERVIEW 162
FIGURE 38 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021) 163
11.1.1.6 Becton, Dickinson and Company 165
TABLE 137 BECTON, DICKINSON, AND COMPANY: BUSINESS OVERVIEW 165
FIGURE 39 BECTON, DICKINSON, AND COMPANY: COMPANY SNAPSHOT (2021) 166
11.1.1.7 Eurofins Scientific 168
TABLE 138 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 168
FIGURE 40 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 168
11.1.1.8 Takara Bio 171
TABLE 139 TAKARA BIO: BUSINESS OVERVIEW 171
FIGURE 41 TAKARA BIO: COMPANY SNAPSHOT (2021) 172
11.1.1.9 Eiken Chemical 174
TABLE 140 EIKEN CHEMICAL: BUSINESS OVERVIEW 174
FIGURE 42 EIKEN CHEMICAL: COMPANY SNAPSHOT (2021) 174
11.1.1.10 Qiagen 176
TABLE 141 QIAGEN: BUSINESS OVERVIEW 176
FIGURE 43 QIAGEN: COMPANY SNAPSHOT (2021) 177
11.1.1.11 Genomadix 179
TABLE 142 GENOMADIX, INC.: BUSINESS OVERVIEW 179
11.2 OTHER PLAYERS 180
11.2.1 INDUSTRIAL/WATER 180
11.2.1.1 Pall Corporation (DANAHER) 180
11.2.1.2 Phigenics, Llc 181
11.2.1.3 Environmental safety technologies 182
11.2.1.4 Hydrosense 182
11.2.1.5 Accepta 183
11.2.1.6 Luminultra technologies 183
11.2.1.7 Bioalert solutions 184
11.2.1.8 Aquacert 184
11.2.1.9 Pacific water technology 185
11.2.1.10 DTK Water 186
11.2.1.11 Sens solutions 186
11.2.2 HEALTHCARE 187
11.2.2.1 Alere (ABBOTT) 187
TABLE 143 ABBOTT: BUSINESS OVERVIEW 187
FIGURE 44 ABBOTT: COMPANY SNAPSHOT (2021) 188
11.2.2.2 Roche Diagnostics 190
TABLE 144 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 190
FIGURE 45 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021) 191
11.2.2.3 Hologic 194
TABLE 145 HOLOGIC: BUSINESS OVERVIEW 194
FIGURE 46 HOLOGIC: COMPANY SNAPSHOT (2021) 195
11.2.2.4 Quidel Corporation 198
TABLE 146 QUIDEL CORPORATION: BUSINESS OVERVIEW 198
FIGURE 47 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 199
11.2.2.5 Pro-Lab Diagnostics 200
*Details on Business Overview, Products Offered, Recent Developments, MnM View, SWOT analysis might not be captured in case of unlisted companies.
12 APPENDIX 201
12.1 DISCUSSION GUIDE 201
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 205
12.3 CUSTOMIZATION OPTIONS 207
12.4 RELATED REPORTS 207
12.5 AUTHOR DETAILS 208



★調査レポート[世界のレジオネラ検査市場（～2027年）：検査種類別（培養、尿中抗原検査、DFA、PCR）、用途別（水＆IVD検査（尿、血液））、エンドユーザー別（病院、クリニック、診断研究所、水処理産業）、地域別] (コード：MD8150-22)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のレジオネラ検査市場（～2027年）：検査種類別（培養、尿中抗原検査、DFA、PCR）、用途別（水＆IVD検査（尿、血液））、エンドユーザー別（病院、クリニック、診断研究所、水処理産業）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の分子診断市場（～2028年）：製品・サービス別（試薬、キット）、検査種類別（研究所、PoC）、検体種類別（血液、尿）、技術別（PCR、INAAT）、用途別（感染症、がん）、エンドユーザー別（診断研究所、病院）、地域別
    MD2521-23 / MarketsandMarkets / 2023年7月3日 / マーケッツアンドマーケッツ社の市場調査によると、世界の分子診断の市場規模は2023年の166億ドルから、CAGR 11.4%成長し、2028年には286億ドルまで拡大すると見込まれています。こちらの資料では、分子診断の世界市場を対象にし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品・サービス別（試薬・キット、機器、サービス・ソフトウェア）分析、検査種類別（研究所検査、PoC検査）分析、検体種類別（血液・血清・血漿、尿、その他）分析、技術別（PCR、INAAT、DNAスクーリング・次世代シークエンシング、in...
  • 世界のCT/NG検査市場（～2028年）：製品別（アッセイ・キット、分析器）、検査種類別（研究室検査、ポイントオブケア検査）、技術別（INAAT、PCR、免疫診断）、エンドユーザー別（診断研究所、病院・診療所）、地域別
    MD8707-23 / MarketsandMarkets / 2023年7月4日 / マーケッツアンドマーケッツ社の市場調査によると、世界のCT/NG検査の市場規模は2023年の17億ドルから、CAGR 8.6%成長し、2028年には27億ドルまで拡大すると見込まれています。こちらの資料では、CT/NG検査の世界市場を対象にし、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別（アッセイ・キット、装置/分析器）分析、検査種類別（研究室検査、ポイントオブケア検査）分析、技術別（PCR、INAAT、免疫診断、その他）分析、エンドユーザー別（診断研究所、病院・診療所）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況、企業情報、隣接・関連市場などについて調査・分析を行いました。なお、当資料に記載されている企業情報には、F....
  • 世界の尿路感染症検査市場2021-2031：感染種類別（尿道炎、膀胱炎、腎盂腎炎）、検査種類別（尿検査、尿培養、感受性試験）、エンドユーザー別（病院、診断研究所、研究機関）、検査キット別（家庭用検査キット、研究所用検査キット）
    ALD23MC097 / Allied Market Research / 2023年1月 / Allied Market...
  • 世界の臨床化学分析装置市場（～2028年）：製品別（全自動＆PoC分析装置、試薬）、検査種類別（基礎代謝、肝臓、腎臓、脂質、甲状腺機能）、エンドユーザー別（病院、クリニック、実験室、研究）、地域別
    MD2843-23 / MarketsandMarkets / 2023年7月11日 / "臨床化学分析装置の世界市場規模は2023年の130億米ドルから2028年には165億米ドルに達すると予測、予測期間中の年平均成長率は4.9%" 臨床化学分析装置市場は様々な要因によって成長を遂げています。主な促進要因としては、高齢者人口の増加、慢性疾患や生活習慣病の有病率の上昇などが挙げられます。さらに、POC検査機器の採用や検査室自動化の需要の高まりも市場拡大に寄与しています。しかし、高い設備投資の必要性、熟練した臨床検査技師の不足、再生品の存在などの課題により、市場の成長は抑制される可能性があります。これらの要因により、当面の市場成長は緩やかになると予想されます。...

    • ◆H&Iグローバルリサーチのお客様（例）◆